Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
This article was originally published in The Pink Sheet Daily
Executive Summary
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.